Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Rapport said its RAP-219 Phase II data in focal onset seizures showed a roughly 78% median reduction in seizure frequency, and it is now actively enrolling Phase III studies. The company also pulled forward the readout for its bipolar mania Phase II trial from 1H 2027 to Q4 2026, while moving RAP-219 into primary generalized tonic-clonic seizures. The update highlights accelerating clinical execution and multiple near-term catalysts for the pipeline.

Analysis

RAPP is transitioning from story stock to binary execution name, which usually changes the shareholder base from discovery-oriented funds to event-driven and biotech-specialist capital. The important second-order effect is that success in focal epilepsy could de-risk the broader RAP-219 platform and compress the time needed for investors to underwrite the bipolar and generalized seizure franchises, effectively increasing the probability-weighted NPV multiple rather than just the near-term peak-sales estimate.

The market is likely underappreciating how much faster a positive Phase III start can matter than the eventual readout. In small-cap biotech, getting studies enrolling cleanly is often a stronger signal of operational quality than headline efficacy, because it validates trial site interest, protocol design, and commercial feasibility; that can support a rerating over the next 1-3 months even before data. The flip side is that any delay in enrollment or safety signal would hit the stock harder than usual because expectations have shifted from optionality to execution.

From a competitive standpoint, a differentiated seizure-reduction profile creates pressure on incumbents with crowded adjunctive epilepsy franchises, especially if physicians begin to view RAP-219 as a potentially higher-efficacy add-on rather than a niche salvage drug. The contrarian risk is that the bar has moved up: once the market prices in platform breadth, the stock becomes vulnerable to dilution from financing or to a sharp drawdown if the expanded indications do not show clean signal separation from placebo. The current setup is best viewed as a catalyst-rich momentum trade with asymmetric downside if the next two milestones slip.

Key Decisions for Investors

• Go long RAPP into Phase III enrollment updates over the next 1-3 months; risk/reward is attractive if the stock is still discounting trial-execution risk, but size modestly because single-program biotech can gap down 25-40% on any setback.
• Buy RAPP call spreads expiring after the Q4 bipolar readout; this captures upside from a second positive data point while capping premium bleed if the stock consolidates before results.
• For hedged exposure, pair long RAPP against a basket short of large-cap epilepsy incumbents (e.g., VRTX/other CNS-adjacent names with slower growth) to isolate platform re-rating rather than sector beta.
• If RAPP rallies sharply on enrollment confirmation, trim 20-30% into strength and retain the rest for data, because the stock may front-run the actual readout and then trade with elevated binary risk.